LGALS3 and diabetes mellitus: At 30 weeks of age, diabetes incidence reached 60.0% in Galectin-3+/+ NOD mice but was significantly reduced to 12.5% in Galectin-3−/− NOD mice (P < 0.01; Fig. 3A).